| Description | MDL-101146, (S)- is an effective orally active inhibitor of human neutrophil elastase. |
| Synonyms | MDL101146, (S)- |
| molecular weight | 632.62 |
| Molecular formula | C29H37F5N4O6 |
| CAS | 163660-59-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Durham SL, Hare CM, Angelastro MR, Burkhart JP, Koehl JR, Marquart AL, Mehdi S, Peet NP, Janusz MJ. Pharmacology of N-[4-(4-morpholinylcarbonyl)benzoyl]-L-valyl-N- [3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]-L-prolinamide (MDL 101,146): a potent orally active inhibitor of human neutrophil elastase. J Pharmacol Exp Ther. 1994 Jul;270(1):185-91. Erratum in: J Pharmacol Exp Ther 1994 Dec;271(3):1720. PubMed PMID: 8035315. 2. Janusz MJ, Durham SL. Inhibition of cartilage degradation in rat collagen-induced arthritis but not adjuvant arthritis by the neutrophil elastase inhibitor MDL 101,146. Inflamm Res. 1997 Dec;46(12):503-8. PubMed PMID: 9459081. 3. Goodarzi M, Bora A, Borota A, Funar-Timofei S, Avram S, Heyden YV. Modeling of 2-pyridin-3-yl-benzo[d][1,3]oxazin-4-one derivatives by several conformational searching tools and molecular docking. Curr Pharm Des. 2013;19(12):2194-203. PubMed PMID: 23016845. |